Research progress on the donor cell sources of pancreatic islet transplantation for treatment of diabetes mellitus_Chinese Journal of Reparative and Reconstructive Surgery

Authors：

ZHU Haitao ^1,2 , ZHANG Xiaoge ¹ , HE Yayi ³ , YU Liang ² , LÜ Yi ^2,4 , PAN Kaili ⁵ ,  WANG Bo ^2,3 ,  CHEN Guoqiang ¹

1. Department of Pediatrics (No. 3 Ward), Northwest Women’s and Children’s Hospital, Xi’an Shaanxi, 710061, P.R.China;
2. Department of Hepatobiliary Surgery, the First Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an Shaanxi, 710061, P.R.China;
3. Department of Endocrinology, the First Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an Shaanxi, 710061, P.R.China;
4. Research Institute of Advanced Surgical Technology and Engineering, Xi’an Jiaotong University, Xi’an Shaanxi, 710061, P.R.China;
5. Department of Pediatrics (No. 2 Ward), Northwest Women’s and Children’s Hospital, Xi’an Shaanxi, 710061, P.R.China;

Corresponding author：

WANG Bo, Email: bobwang75@yeah.net; CHEN Guoqiang, Email: drchengq@163.com

Keywords：

Islet transplantation; donator; type 1 diabetes mellitus; stem cells; xenotransplantation

DOI：

10.7507/1002-1892.201707049

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the research progress on the source and selection of donor cells in the field of islet replacement therapy for diabetes mellitus. Methods Domestic and abroad literature concerning islet replacement therapy for diabetes mellitus, as well as donor source and donor selection was reviewed and analyzed thoroughly. Results The shortage of donor supply is still a major obstacle for the widely clinical application of pancreatic islet transplantation (PIT). Currently, in addition to the progress on the allogeneic/autologous donor islet supply, some remarkable achievements have been also attained in the application of xenogeneic islet (from pig donor), as well as islet like cells derived from stem cells and islet cell line, potentially enlarging the source of implantable cells. Conclusion Adequate and suitable donor cell supply is an essential prerequisite for widely clinical application of PIT therapy for type 1 diabetes mellitus (T1DM). Further perfection of organ donation system, together with development of immune-tolerance induction, gene and bioengineering technology etc. will possibly solve the problem of donor cell shortage and provide a basis for clinical application of cellular replacement therapy for T1DM.

Citation： ZHU Haitao, ZHANG Xiaoge, HE Yayi, YU Liang, LÜ Yi, PAN Kaili, WANG Bo, CHEN Guoqiang. Research progress on the donor cell sources of pancreatic islet transplantation for treatment of diabetes mellitus. Chinese Journal of Reparative and Reconstructive Surgery, 2018, 32(1): 104-111. doi: 10.7507/1002-1892.201707049 Copy

1.	Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet, 2014, 383(9911): 69-82.
2.	Diaz-Valencia PA, Bougnères P, Valleron AJ. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health, 2015, 15: 255.
3.	迟家敏. 实用糖尿病学. 4版. 北京: 人民卫生出版社, 2015: 2-9.
4.	Fotino N, Fotino C, Pileggi A. Re-engineering islet cell transplantation. Pharmacol Res, 2015, 98: 76-85.
5.	Hering BJ, Clarke WR, Bridges ND, et al. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care, 2016, 39(7): 1230-1240.
6.	Wisel SA, Braun HJ, Stock PG. Current outcomes in islet versus solid organ pancreas transplant for beta-cell replacement in type 1 diabetes. Curr Opin Organ Transplant, 2016, 21(4): 399-404.
7.	Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005, 353(25): 2643-2653.
8.	Ludwig B, Ludwig S, Steffen A, et al. Islet versus pancreas transplantation in type 1 diabetes: competitive or complementary? Curr Diab Rep, 2010, 10(6): 506-511.
9.	Farney AC, Sutherland DE, Opara EC. Evolution of Islet Transplantation for the Last 30 Years. Pancreas, 2016, 45(1): 8-20.
10.	Bartlett ST, Markmann JF, Johnson P, et al. Report from IPITA-TTS Opinion Leaders Meeting on the Future of beta-Cell Replacement. Transplantation, 2016, 100 Suppl 2: S1-44.
11.	Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med, 2000, 343(4): 230-238.
12.	Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant, 2012, 12(6): 1576-1583.
13.	Lehmann R, Graziano J, Brockmann J, et al. Glycemic Control in Simultaneous Islet-Kidney Versus Pancreas-Kidney Transplantation in Type 1 Diabetes: A Prospective 13-Year Follow-up. Diabetes Care, 2015, 38(5): 752-759.
14.	Balamurugan AN, Naziruddin B, Lockridge A, et al. Islet product characteristics and factors related to successful human islet transplantation from the Collaborative Islet Transplant Registry (CITR) 1999-2010. Am J Transplant, 2014, 14(11): 2595-2606.
15.	Moassesfar S, Masharani U, Frassetto LA, et al. A Comparative Analysis of the Safety, Efficacy, and Cost of Islet Versus Pancreas Transplantation in Nonuremic Patients With Type 1 Diabetes. Am J Transplant, 2016, 16(2): 518-526.
16.	Lablanche S, Borot S, Wojtusciszyn A, et al. Five-Year Metabolic, Functional, and Safety Results of Patients With Type 1 Diabetes Transplanted With Allogenic Islets Within the Swiss-French GRAGIL Network. Diabetes Care, 2015, 38(9): 1714-1722.
17.	Kandaswamy R, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2013 Annual Data Report: pancreas. Am J Transplant, 2015, 15 Suppl 2: 1-20.
18.	Brennan DC, Kopetskie HA, Sayre PH, et al. Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States. Am J Transplant, 2016, 16(2): 509-517.
19.	Markmann JF, Bartlett ST, Johnson P, et al. Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of beta-Cell Replacement. Transplantation, 2016, 100(7): e25-31.
20.	Matsumoto S, Okitsu T, Iwanaga Y, et al. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet, 2005, 365(9471): 1642-1644.
21.	Matsumoto S, Okitsu T, Iwanaga Y, et al. Follow-up study of the first successful living donor islet transplantation. Transplantation, 2006, 82(12): 1629-1633.
22.	Paget M, Murray H, Bailey CJ, et al. Human islet isolation: semi-automated and manual methods. Diab Vasc Dis Res, 2007, 4(1): 7-12.
23.	Israni AK, Zaun D, Rosendale JD, et al. OPTN/SRTR 2012 Annual Data Report: deceased organ donation. Am J Transplant, 2014, 14 Suppl 1: 167-183.
24.	Israni AK, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2012 Annual Data Report: pancreas. Am J Transplant, 2014, 14 Suppl 1: 45-68.
25.	Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA, 2005, 293(7): 830-835.
26.	Al-Adra DP, Gill RS, Imes S, et al. Single-donor islet transplantation and long-term insulin independence in select patients with type 1 diabetes mellitus. Transplantation, 2014, 98(9): 1007-1012.
27.	Shapiro AM. Strategies toward single-donor islets of Langerhans transplantation. Curr Opin Organ Transplant, 2011, 16(6): 627-631.
28.	O’Gorman D, Kin T, Murdoch T, et al. The standardization of pancreatic donors for islet isolation. Transplant Proc, 2005, 37(2): 1309-1310.
29.	Witkowski P, Liu Z, Cernea S, et al. Validation of the scoring system for standardization of the pancreatic donor for islet isolation as used in a new islet isolation center. Transplant Proc, 2006, 38(9): 3039-3040.
30.	Bruni A, Gala-Lopez B, Pepper AR, et al. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab Syndr Obes, 2014, 7: 211-223.
31.	Ponte GM, Pileggi A, Messinger S, et al. Toward maximizing the success rates of human islet isolation: influence of donor and isolation factors. Cell Transplant, 2007, 16(6): 595-607.
32.	Wang LJ, Cochet O, Wang XJ, et al. Donor height in combination with islet donor score improves pancreas donor selection for pancreatic islet isolation and transplantation. Transplant Proc, 2014, 46(6): 1972-1974.
33.	Niclauss N, Bosco D, Morel P, et al. Influence of donor age on islet isolation and transplantation outcome. Transplantation, 2011, 91(3): 360-366.
34.	Hilling DE, Bouwman E, Terpstra OT, et al. Effects of donor-, pancreas-, and isolation-related variables on human islet isolation outcome: a systematic review. Cell Transplant, 2014, 23(8): 921-928.
35.	Kaddis JS, Danobeitia JS, Niland JC, et al. Multicenter analysis of novel and established variables associated with successful human islet isolation outcomes. Am J Transplant, 2010, 10(3): 646-656.
36.	Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care, 2012, 35(7): 1436-1445.
37.	Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes, 2004, 53(3): 624-632.
38.	Kin T, Murdoch TB, Shapiro AM, et al. Estimation of pancreas weight from donor variables. Cell Transplant, 2006, 15(2): 181-185.
39.	Markmann JF, Deng S, Desai NM, et al. The use of non-heart-beating donors for isolated pancreatic islet transplantation. Transplantation, 2003, 75(9): 1423-1429.
40.	Andres A, Kin T, O’Gorman D, et al. Clinical islet isolation and transplantation outcomes with deceased cardiac death donors are similar to neurological determination of death donors. Transpl Int, 2016, 29(1): 34-40.
41.	Ricordi C, Goldstein JS, Balamurugan AN, et al. National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes, 2016, 65(11): 3418-3428.
42.	Anazawa T, Saito T, Goto M, et al. Long-term outcomes of clinical transplantation of pancreatic islets with uncontrolled donors after cardiac death: a multicenter experience in Japan. Transplant Proc, 2014, 46(6): 1980-1984.
43.	Berney T, Boffa C, Augustine T, et al. Utilization of organs from donors after circulatory death for vascularized pancreas and islet of Langerhans transplantation: recommendations from an expert group. Transpl Int, 2016, 29(7): 798-806.
44.	Saito T, Gotoh M, Satomi S, et al. Islet transplantation using donors after cardiac death: report of the Japan Islet Transplantation Registry. Transplantation, 2010, 90(7): 740-747.
45.	郑树森. 中国器官捐献与移植现状. 武汉大学学报 (医学版), 2016, 37(4): 523-525.
46.	Wilson GC, Sutton JM, Smith MT, et al. Total pancreatectomy with islet cell autotransplantation as the initial treatment for minimal-change chronic pancreatitis. HPB (Oxford), 2015, 17(3): 232-238.
47.	Chinnakotla S, Bellin MD, Schwarzenberg SJ, et al. Total pancreatectomy and islet autotransplantation in children for chronic pancreatitis: indication, surgical techniques, postoperative management, and long-term outcomes. Ann Surg, 2014, 260(1): 56-64.
48.	Sutherland DE, Radosevich DM, Bellin MD, et al. Total pancreatectomy and islet autotransplantation for chronic pancreatitis. J Am Coll Surg, 2012, 214(4): 409-426.
49.	Geyer MC, Coates PT, Khurana S, et al. First Report of Successful Total Pancreatectomy and Islet Autotransplant in Australia. Pancreas, 2017, 46(3): e18-e20.
50.	Savari O, Golab K, Wang LJ, et al. Preservation of beta cell function after pancreatic islet autotransplantation: University of Chicago experience. Am Surg, 2015, 81(4): 421-427.
51.	Zhu HT, Yu L, Lyu Y, et al. Optimal pig donor selection in islet xenotransplantation: current status and future perspectives. J Zhejiang Univ Sci B, 2014, 15(8): 681-691.
52.	Zhu H, Yu L, He Y, et al. Microencapsulated Pig Islet Xenotransplantation as an Alternative Treatment of Diabetes. Tissue Eng Part B Rev, 2015, 21(5): 474-489.
53.	Nagaraju S, Bottino R, Wijkstrom M, et al. Islet xenotransplantation: what is the optimal age of the islet-source pig? Xenotransplantation, 2015, 22(1): 7-19.
54.	朱海涛, 于良, 王博. 猪胰岛细胞分离纯化研究进展. 中国修复重建外科杂志, 2012, 26(8): 1012-1016.
55.	Dufrane D, Goebbels RM, Fdilat I, et al. Impact of porcine islet size on cellular structure and engraftment after transplantation: adult versus young pigs. Pancreas, 2005, 30(2): 138-147.
56.	Bottino R, Balamurugan AN, Smetanka C, et al. Isolation outcome and functional characteristics of young and adult pig pancreatic islets for transplantation studies. Xenotransplantation, 2007, 14(1): 74-82.
57.	Rajotte RV. Isolation and assessment of islet quality. Xenotransplantation, 2008, 15(2): 93-95.
58.	Luca G, Nastruzzi C, Calvitti M, et al. Accelerated functional maturation of isolated neonatal porcine cell clusters: in vitro and in vivo results in NOD mice. Cell Transplant, 2005, 14(5): 249-261.
59.	Juang JH, Hsu BR, Kuo CH, et al. Characteristics and transplantation of the porcine neonatal pancreatic cell clusters isolated from 1- to 3-day-old versus 1-month-old pigs. Transplant Proc, 2004, 36(4): 1203-1205.
60.	Cooper DK, Ekser B, Ramsoondar J, et al. The role of genetically engineered pigs in xenotransplantation research. J Pathol, 2016, 238(2): 288-299.
61.	Klymiuk N, Ludwig B, Seissler J, et al. Current Concepts of Using Pigs as a Source for Beta-Cell Replacement Therapy of Type 1 Diabetes. Current Molecular Biology Reports, 2016, 2(2): 73-82.
62.	Wijkstrom M, Bottino R, Iwase H, et al. Glucose metabolism in pigs expressing human genes under an insulin promoter. Xenotransplantation, 2015, 22(1): 70-79.
63.	Salama A, Mosser M, Lévêque X, et al. Neu5Gc and α1-3 GAL Xenoantigen Knockout Does Not Affect Glycemia Homeostasis and Insulin Secretion in Pigs. Diabetes, 2017, 66(4): 987-993.
64.	Ma X, Ye B, Gao F, et al. Tissue factor knockdown in porcine islets: an effective approach to suppressing the instant blood-mediated inflammatory reaction. Cell Transplant, 2012, 21(1): 61-71.
65.	Hawthorne WJ, Salvaris EJ, Phillips P, et al. Control of IBMIR in neonatal porcine islet xenotransplantation in baboons. Am J Transplant, 2014, 14(6): 1300-1309.
66.	Jung YS, Jeong JH, Yook S, et al. Surface modification of pancreatic islets using heparin-DOPA conjugate and anti-CD154 mAb for the prolonged survival of intrahepatic transplanted islets in a xenograft model. Biomaterials, 2012, 33(1): 295-303.
67.	Salomon DR. A CRISPR Way to Block PERVs－Engineering Organs for Transplantation. N Engl J Med, 2016, 374(11): 1089-1091.
68.	D’Amour KA, Bang AG, Eliazer S, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol, 2006, 24(11): 1392-1401.
69.	Zhang D, Jiang W, Liu M, et al. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res, 2009, 19(4): 429-438.
70.	Jafarian A, Taghikhani M, Abroun S, et al. Generation of high-yield insulin producing cells from human bone marrow mesenchymal stem cells. Mol Biol Rep, 2014, 41(7): 4783-4794.
71.	曹玫, 张剑波, 叶尚勉, 等. 妊娠早期人脐带血管周围细胞的分离培养及定向分化胰岛样细胞的研究. 中国修复重建外科杂志, 2014, 28(9): 1156-1160.
72.	Henley KD, Stanescu DE, Kropp PA, et al. Threshold-Dependent Cooperativity of Pdx1 and Oc1 in Pancreatic Progenitors Establishes Competency for Endocrine Differentiation and beta-Cell Function. Cell Rep, 2016, 15(12): 2637-2650.
73.	Klein D, Alvarez-Cubela S, Lanzoni G, et al. BMP-7 Induces Adult Human Pancreatic Exocrine-to-Endocrine Conversion. Diabetes, 2015, 64(12): 4123-4134.
74.	Banga A, Akinci E, Greder LV, et al. In vivo reprogramming of Sox9+ cells in the liver to insulin-secreting ducts. Proc Natl Acad Sci U S A, 2012, 109(38): 15336-15341.
75.	Khosravi-Maharlooei M, Hajizadeh-Saffar E, Tahamtani Y, et al. THERAPY OF ENDOCRINE DISEASE: Islet transplantation for type 1 diabetes: so close and yet so far away. Eur J Endocrinol, 2015, 173(5): R165-183.
76.	Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol, 2008, 26(4): 443-452.
77.	Pagliuca FW, Millman JR, Gurtler M, et al. Generation of functional human pancreatic beta cells in vitro. Cell, 2014, 159(2): 428-439.
78.	Jeon K, Lim H, Kim JH, et al. Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. Stem Cells Dev, 2012, 21(14): 2642-2655.
79.	Alipio Z, Liao W, Roemer EJ, et al. Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. Proc Natl Acad Sci U S A, 2010, 107(30): 13426-13431.
80.	Fu X. The immunogenicity of cells derived from induced pluripotent stem cells. Cell Mol Immunol, 2014, 11(1): 14-16.
81.	Zhou Q, Brown J, Kanarek A, et al. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature, 2008, 455(7213): 627-632.
82.	Hill CM, Banga A, Abrahante JE, et al. Establishing a large animal model for in vivo reprogramming of bile duct cells into insulin secreting cells to treat diabetes. Hum Gene Ther Clin Dev, 2017, 28(2): 87-95.
83.	Li W, Nakanishi M, Zumsteg A, et al. In vivo reprogramming of pancreatic acinar cells to three islet endocrine subtypes. Elife, 2014, 3: e01846.
84.	Lima MJ, Muir KR, Docherty HM, et al. Generation of functional beta-like cells from human exocrine pancreas. PLoS One, 2016, 11(5): e0156204.
85.	Thakkar UG, Trivedi HL, Vanikar AV, et al. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy, 2015, 17(7): 940-947.
86.	Cai J, Wu Z, Xu X, et al. Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion. Diabetes Care, 2016, 39(1): 149-157.
87.	Guan LX, Guan H, Li HB, et al. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Exp Ther Med, 2015, 9(5): 1623-1630.
88.	Pan XH, Huang X, Ruan GP, et al. Umbilical cord mesenchymal stem cells are able to undergo differentiation into functional islet-like cells in type 2 diabetic tree shrews. Mol Cell Probes, 2017: 1-12.
89.	Abdelalim EM, Emara MM. Advances and challenges in the differentiation of pluripotent stem cells into pancreatic beta cells. World J Stem Cells, 2015, 7(1): 174-181.
90.	Scharfmann R, Pechberty S, Hazhouz Y, et al. Development of a conditionally immortalized human pancreatic beta cell line. J Clin Invest, 2014, 124(5): 2087-2098.
91.	Ravassard P, Hazhouz Y, Pechberty S, et al. A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion. J Clin Invest, 2011, 121(9): 3589-3597.
92.	McClenaghan NH, Flatt PR. Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines. Diabetes Obes Metab, 1999, 1(3): 137-150.
93.	Hohmeier HE, Newgard CB. Cell lines derived from pancreatic islets. Mol Cell Endocrinol, 2004, 228(1-2): 121-128.
94.	刘铮, 只德贤, 王敏伟. 胰岛细胞系模型的研究进展. 沈阳药科大学学报, 2007, 24(1): 61-64.

1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet, 2014, 383(9911): 69-82.
2. Diaz-Valencia PA, Bougnères P, Valleron AJ. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health, 2015, 15: 255.
3. 迟家敏. 实用糖尿病学. 4版. 北京: 人民卫生出版社, 2015: 2-9.
4. Fotino N, Fotino C, Pileggi A. Re-engineering islet cell transplantation. Pharmacol Res, 2015, 98: 76-85.
5. Hering BJ, Clarke WR, Bridges ND, et al. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care, 2016, 39(7): 1230-1240.
6. Wisel SA, Braun HJ, Stock PG. Current outcomes in islet versus solid organ pancreas transplant for beta-cell replacement in type 1 diabetes. Curr Opin Organ Transplant, 2016, 21(4): 399-404.
7. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005, 353(25): 2643-2653.
8. Ludwig B, Ludwig S, Steffen A, et al. Islet versus pancreas transplantation in type 1 diabetes: competitive or complementary? Curr Diab Rep, 2010, 10(6): 506-511.
9. Farney AC, Sutherland DE, Opara EC. Evolution of Islet Transplantation for the Last 30 Years. Pancreas, 2016, 45(1): 8-20.
10. Bartlett ST, Markmann JF, Johnson P, et al. Report from IPITA-TTS Opinion Leaders Meeting on the Future of beta-Cell Replacement. Transplantation, 2016, 100 Suppl 2: S1-44.
11. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med, 2000, 343(4): 230-238.
12. Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant, 2012, 12(6): 1576-1583.
13. Lehmann R, Graziano J, Brockmann J, et al. Glycemic Control in Simultaneous Islet-Kidney Versus Pancreas-Kidney Transplantation in Type 1 Diabetes: A Prospective 13-Year Follow-up. Diabetes Care, 2015, 38(5): 752-759.
14. Balamurugan AN, Naziruddin B, Lockridge A, et al. Islet product characteristics and factors related to successful human islet transplantation from the Collaborative Islet Transplant Registry (CITR) 1999-2010. Am J Transplant, 2014, 14(11): 2595-2606.
15. Moassesfar S, Masharani U, Frassetto LA, et al. A Comparative Analysis of the Safety, Efficacy, and Cost of Islet Versus Pancreas Transplantation in Nonuremic Patients With Type 1 Diabetes. Am J Transplant, 2016, 16(2): 518-526.
16. Lablanche S, Borot S, Wojtusciszyn A, et al. Five-Year Metabolic, Functional, and Safety Results of Patients With Type 1 Diabetes Transplanted With Allogenic Islets Within the Swiss-French GRAGIL Network. Diabetes Care, 2015, 38(9): 1714-1722.
17. Kandaswamy R, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2013 Annual Data Report: pancreas. Am J Transplant, 2015, 15 Suppl 2: 1-20.
18. Brennan DC, Kopetskie HA, Sayre PH, et al. Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States. Am J Transplant, 2016, 16(2): 509-517.
19. Markmann JF, Bartlett ST, Johnson P, et al. Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of beta-Cell Replacement. Transplantation, 2016, 100(7): e25-31.
20. Matsumoto S, Okitsu T, Iwanaga Y, et al. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet, 2005, 365(9471): 1642-1644.
21. Matsumoto S, Okitsu T, Iwanaga Y, et al. Follow-up study of the first successful living donor islet transplantation. Transplantation, 2006, 82(12): 1629-1633.
22. Paget M, Murray H, Bailey CJ, et al. Human islet isolation: semi-automated and manual methods. Diab Vasc Dis Res, 2007, 4(1): 7-12.
23. Israni AK, Zaun D, Rosendale JD, et al. OPTN/SRTR 2012 Annual Data Report: deceased organ donation. Am J Transplant, 2014, 14 Suppl 1: 167-183.
24. Israni AK, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2012 Annual Data Report: pancreas. Am J Transplant, 2014, 14 Suppl 1: 45-68.
25. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA, 2005, 293(7): 830-835.
26. Al-Adra DP, Gill RS, Imes S, et al. Single-donor islet transplantation and long-term insulin independence in select patients with type 1 diabetes mellitus. Transplantation, 2014, 98(9): 1007-1012.
27. Shapiro AM. Strategies toward single-donor islets of Langerhans transplantation. Curr Opin Organ Transplant, 2011, 16(6): 627-631.
28. O’Gorman D, Kin T, Murdoch T, et al. The standardization of pancreatic donors for islet isolation. Transplant Proc, 2005, 37(2): 1309-1310.
29. Witkowski P, Liu Z, Cernea S, et al. Validation of the scoring system for standardization of the pancreatic donor for islet isolation as used in a new islet isolation center. Transplant Proc, 2006, 38(9): 3039-3040.
30. Bruni A, Gala-Lopez B, Pepper AR, et al. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab Syndr Obes, 2014, 7: 211-223.
31. Ponte GM, Pileggi A, Messinger S, et al. Toward maximizing the success rates of human islet isolation: influence of donor and isolation factors. Cell Transplant, 2007, 16(6): 595-607.
32. Wang LJ, Cochet O, Wang XJ, et al. Donor height in combination with islet donor score improves pancreas donor selection for pancreatic islet isolation and transplantation. Transplant Proc, 2014, 46(6): 1972-1974.
33. Niclauss N, Bosco D, Morel P, et al. Influence of donor age on islet isolation and transplantation outcome. Transplantation, 2011, 91(3): 360-366.
34. Hilling DE, Bouwman E, Terpstra OT, et al. Effects of donor-, pancreas-, and isolation-related variables on human islet isolation outcome: a systematic review. Cell Transplant, 2014, 23(8): 921-928.
35. Kaddis JS, Danobeitia JS, Niland JC, et al. Multicenter analysis of novel and established variables associated with successful human islet isolation outcomes. Am J Transplant, 2010, 10(3): 646-656.
36. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care, 2012, 35(7): 1436-1445.
37. Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes, 2004, 53(3): 624-632.
38. Kin T, Murdoch TB, Shapiro AM, et al. Estimation of pancreas weight from donor variables. Cell Transplant, 2006, 15(2): 181-185.
39. Markmann JF, Deng S, Desai NM, et al. The use of non-heart-beating donors for isolated pancreatic islet transplantation. Transplantation, 2003, 75(9): 1423-1429.
40. Andres A, Kin T, O’Gorman D, et al. Clinical islet isolation and transplantation outcomes with deceased cardiac death donors are similar to neurological determination of death donors. Transpl Int, 2016, 29(1): 34-40.
41. Ricordi C, Goldstein JS, Balamurugan AN, et al. National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes, 2016, 65(11): 3418-3428.
42. Anazawa T, Saito T, Goto M, et al. Long-term outcomes of clinical transplantation of pancreatic islets with uncontrolled donors after cardiac death: a multicenter experience in Japan. Transplant Proc, 2014, 46(6): 1980-1984.
43. Berney T, Boffa C, Augustine T, et al. Utilization of organs from donors after circulatory death for vascularized pancreas and islet of Langerhans transplantation: recommendations from an expert group. Transpl Int, 2016, 29(7): 798-806.
44. Saito T, Gotoh M, Satomi S, et al. Islet transplantation using donors after cardiac death: report of the Japan Islet Transplantation Registry. Transplantation, 2010, 90(7): 740-747.
45. 郑树森. 中国器官捐献与移植现状. 武汉大学学报 (医学版), 2016, 37(4): 523-525.
46. Wilson GC, Sutton JM, Smith MT, et al. Total pancreatectomy with islet cell autotransplantation as the initial treatment for minimal-change chronic pancreatitis. HPB (Oxford), 2015, 17(3): 232-238.
47. Chinnakotla S, Bellin MD, Schwarzenberg SJ, et al. Total pancreatectomy and islet autotransplantation in children for chronic pancreatitis: indication, surgical techniques, postoperative management, and long-term outcomes. Ann Surg, 2014, 260(1): 56-64.
48. Sutherland DE, Radosevich DM, Bellin MD, et al. Total pancreatectomy and islet autotransplantation for chronic pancreatitis. J Am Coll Surg, 2012, 214(4): 409-426.
49. Geyer MC, Coates PT, Khurana S, et al. First Report of Successful Total Pancreatectomy and Islet Autotransplant in Australia. Pancreas, 2017, 46(3): e18-e20.
50. Savari O, Golab K, Wang LJ, et al. Preservation of beta cell function after pancreatic islet autotransplantation: University of Chicago experience. Am Surg, 2015, 81(4): 421-427.
51. Zhu HT, Yu L, Lyu Y, et al. Optimal pig donor selection in islet xenotransplantation: current status and future perspectives. J Zhejiang Univ Sci B, 2014, 15(8): 681-691.
52. Zhu H, Yu L, He Y, et al. Microencapsulated Pig Islet Xenotransplantation as an Alternative Treatment of Diabetes. Tissue Eng Part B Rev, 2015, 21(5): 474-489.
53. Nagaraju S, Bottino R, Wijkstrom M, et al. Islet xenotransplantation: what is the optimal age of the islet-source pig? Xenotransplantation, 2015, 22(1): 7-19.
54. 朱海涛, 于良, 王博. 猪胰岛细胞分离纯化研究进展. 中国修复重建外科杂志, 2012, 26(8): 1012-1016.
55. Dufrane D, Goebbels RM, Fdilat I, et al. Impact of porcine islet size on cellular structure and engraftment after transplantation: adult versus young pigs. Pancreas, 2005, 30(2): 138-147.
56. Bottino R, Balamurugan AN, Smetanka C, et al. Isolation outcome and functional characteristics of young and adult pig pancreatic islets for transplantation studies. Xenotransplantation, 2007, 14(1): 74-82.
57. Rajotte RV. Isolation and assessment of islet quality. Xenotransplantation, 2008, 15(2): 93-95.
58. Luca G, Nastruzzi C, Calvitti M, et al. Accelerated functional maturation of isolated neonatal porcine cell clusters: in vitro and in vivo results in NOD mice. Cell Transplant, 2005, 14(5): 249-261.
59. Juang JH, Hsu BR, Kuo CH, et al. Characteristics and transplantation of the porcine neonatal pancreatic cell clusters isolated from 1- to 3-day-old versus 1-month-old pigs. Transplant Proc, 2004, 36(4): 1203-1205.
60. Cooper DK, Ekser B, Ramsoondar J, et al. The role of genetically engineered pigs in xenotransplantation research. J Pathol, 2016, 238(2): 288-299.
61. Klymiuk N, Ludwig B, Seissler J, et al. Current Concepts of Using Pigs as a Source for Beta-Cell Replacement Therapy of Type 1 Diabetes. Current Molecular Biology Reports, 2016, 2(2): 73-82.
62. Wijkstrom M, Bottino R, Iwase H, et al. Glucose metabolism in pigs expressing human genes under an insulin promoter. Xenotransplantation, 2015, 22(1): 70-79.
63. Salama A, Mosser M, Lévêque X, et al. Neu5Gc and α1-3 GAL Xenoantigen Knockout Does Not Affect Glycemia Homeostasis and Insulin Secretion in Pigs. Diabetes, 2017, 66(4): 987-993.
64. Ma X, Ye B, Gao F, et al. Tissue factor knockdown in porcine islets: an effective approach to suppressing the instant blood-mediated inflammatory reaction. Cell Transplant, 2012, 21(1): 61-71.
65. Hawthorne WJ, Salvaris EJ, Phillips P, et al. Control of IBMIR in neonatal porcine islet xenotransplantation in baboons. Am J Transplant, 2014, 14(6): 1300-1309.
66. Jung YS, Jeong JH, Yook S, et al. Surface modification of pancreatic islets using heparin-DOPA conjugate and anti-CD154 mAb for the prolonged survival of intrahepatic transplanted islets in a xenograft model. Biomaterials, 2012, 33(1): 295-303.
67. Salomon DR. A CRISPR Way to Block PERVs－Engineering Organs for Transplantation. N Engl J Med, 2016, 374(11): 1089-1091.
68. D’Amour KA, Bang AG, Eliazer S, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol, 2006, 24(11): 1392-1401.
69. Zhang D, Jiang W, Liu M, et al. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res, 2009, 19(4): 429-438.
70. Jafarian A, Taghikhani M, Abroun S, et al. Generation of high-yield insulin producing cells from human bone marrow mesenchymal stem cells. Mol Biol Rep, 2014, 41(7): 4783-4794.
71. 曹玫, 张剑波, 叶尚勉, 等. 妊娠早期人脐带血管周围细胞的分离培养及定向分化胰岛样细胞的研究. 中国修复重建外科杂志, 2014, 28(9): 1156-1160.
72. Henley KD, Stanescu DE, Kropp PA, et al. Threshold-Dependent Cooperativity of Pdx1 and Oc1 in Pancreatic Progenitors Establishes Competency for Endocrine Differentiation and beta-Cell Function. Cell Rep, 2016, 15(12): 2637-2650.
73. Klein D, Alvarez-Cubela S, Lanzoni G, et al. BMP-7 Induces Adult Human Pancreatic Exocrine-to-Endocrine Conversion. Diabetes, 2015, 64(12): 4123-4134.
74. Banga A, Akinci E, Greder LV, et al. In vivo reprogramming of Sox9+ cells in the liver to insulin-secreting ducts. Proc Natl Acad Sci U S A, 2012, 109(38): 15336-15341.
75. Khosravi-Maharlooei M, Hajizadeh-Saffar E, Tahamtani Y, et al. THERAPY OF ENDOCRINE DISEASE: Islet transplantation for type 1 diabetes: so close and yet so far away. Eur J Endocrinol, 2015, 173(5): R165-183.
76. Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol, 2008, 26(4): 443-452.
77. Pagliuca FW, Millman JR, Gurtler M, et al. Generation of functional human pancreatic beta cells in vitro. Cell, 2014, 159(2): 428-439.
78. Jeon K, Lim H, Kim JH, et al. Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. Stem Cells Dev, 2012, 21(14): 2642-2655.
79. Alipio Z, Liao W, Roemer EJ, et al. Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. Proc Natl Acad Sci U S A, 2010, 107(30): 13426-13431.
80. Fu X. The immunogenicity of cells derived from induced pluripotent stem cells. Cell Mol Immunol, 2014, 11(1): 14-16.
81. Zhou Q, Brown J, Kanarek A, et al. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature, 2008, 455(7213): 627-632.
82. Hill CM, Banga A, Abrahante JE, et al. Establishing a large animal model for in vivo reprogramming of bile duct cells into insulin secreting cells to treat diabetes. Hum Gene Ther Clin Dev, 2017, 28(2): 87-95.
83. Li W, Nakanishi M, Zumsteg A, et al. In vivo reprogramming of pancreatic acinar cells to three islet endocrine subtypes. Elife, 2014, 3: e01846.
84. Lima MJ, Muir KR, Docherty HM, et al. Generation of functional beta-like cells from human exocrine pancreas. PLoS One, 2016, 11(5): e0156204.
85. Thakkar UG, Trivedi HL, Vanikar AV, et al. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy, 2015, 17(7): 940-947.
86. Cai J, Wu Z, Xu X, et al. Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion. Diabetes Care, 2016, 39(1): 149-157.
87. Guan LX, Guan H, Li HB, et al. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Exp Ther Med, 2015, 9(5): 1623-1630.
88. Pan XH, Huang X, Ruan GP, et al. Umbilical cord mesenchymal stem cells are able to undergo differentiation into functional islet-like cells in type 2 diabetic tree shrews. Mol Cell Probes, 2017: 1-12.
89. Abdelalim EM, Emara MM. Advances and challenges in the differentiation of pluripotent stem cells into pancreatic beta cells. World J Stem Cells, 2015, 7(1): 174-181.
90. Scharfmann R, Pechberty S, Hazhouz Y, et al. Development of a conditionally immortalized human pancreatic beta cell line. J Clin Invest, 2014, 124(5): 2087-2098.
91. Ravassard P, Hazhouz Y, Pechberty S, et al. A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion. J Clin Invest, 2011, 121(9): 3589-3597.
92. McClenaghan NH, Flatt PR. Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines. Diabetes Obes Metab, 1999, 1(3): 137-150.
93. Hohmeier HE, Newgard CB. Cell lines derived from pancreatic islets. Mol Cell Endocrinol, 2004, 228(1-2): 121-128.
94. 刘铮, 只德贤, 王敏伟. 胰岛细胞系模型的研究进展. 沈阳药科大学学报, 2007, 24(1): 61-64.

Chinese Journal of Reparative and Reconstructive Surgery

Research progress on the donor cell sources of pancreatic islet transplantation for treatment of diabetes mellitus

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content